Emergent BioSolutions (EBS) Tops Q3 EPS by 28c
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $8.45 +5.49%
EPS Growth %: -31.3%
Financial Fact:
Contracts and grants: 31.5M
Today's EPS Names:
DTGI, CRMT, MAYS, More
EPS Growth %: -31.3%
Financial Fact:
Contracts and grants: 31.5M
Today's EPS Names:
DTGI, CRMT, MAYS, More
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q3 EPS of $0.83, $0.28 better than the analyst estimate of $0.55. Revenue for the quarter came in at $164.9 million versus the consensus estimate of $151.42 million.
Emergent BioSolutions sees FY2015 revenue of $510-540 million.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JPMorgan raises S&P 500 target to 7,800, says earnings revision ’unprecedented’
- NXP Semiconductors names Mike Lucarelli as new investor relations head
- Paychex beats fourth quarter EPS estimates, stock slides
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
